Clofarabine plus low-dose cytarabine is as effective as and less toxic than intensive chemotherapy in elderly AML patients

Most patient with acute myeloid leukemia (AML) age ≥ 60 are not offered intensive induction because of high mortality. Phase 2 studies of clofarabine plus low-dose cytarabine (CLDA) as frontline therapy for elderly AML patients demonstrated high response and acceptable toxicity. We hypothesized that...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Clin Lymphoma Myeloma Leuk
Auteurs principaux: Takahashi, Koichi, Kantarjian, Hagop, Garcia-Manero, Guillermo, Borthakur, Gautam, Kadia, Tapan, DiNardo, Courtney, Jabbour, Elias, Pierce, Sherry, Estrov, Zeev, Konopleva, Marina, Andreeff, Michael, Ravandi, Farhad, Cortes, Jorge
Format: Artigo
Langue:Inglês
Publié: 2015
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4804759/
https://ncbi.nlm.nih.gov/pubmed/26752456
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clml.2015.11.016
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires